Wall Street brokerages predict that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will post earnings per share of ($0.37) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.40). ACADIA Pharmaceuticals reported earnings of ($0.50) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 26%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 25th.

On average, analysts expect that ACADIA Pharmaceuticals will report full year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.59). For the next financial year, analysts forecast that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($2.11) to $0.45. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.11. ACADIA Pharmaceuticals had a negative net margin of 82.48% and a negative return on equity of 50.15%. The business had revenue of $94.59 million for the quarter, compared to analyst estimates of $88.49 million. During the same period last year, the firm earned ($0.50) earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 62.2% compared to the same quarter last year.

Several research firms recently commented on ACAD. Stifel Nicolaus set a $39.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, September 9th. Bank of America set a $31.00 price target on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Leerink Swann upgraded shares of ACADIA Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $21.00 to $50.00 in a research report on Friday, September 13th. ValuEngine downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $49.80.

In other news, insider Eric Alejandro Miller sold 4,645 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $41.18, for a total value of $191,281.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker bought 1,562,500 shares of ACADIA Pharmaceuticals stock in a transaction dated Friday, September 20th. The stock was purchased at an average price of $40.00 per share, with a total value of $62,500,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 97,942 shares of company stock valued at $3,840,880 in the last 90 days. 29.40% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. AdvisorNet Financial Inc acquired a new stake in shares of ACADIA Pharmaceuticals during the third quarter valued at about $27,000. North Star Investment Management Corp. acquired a new position in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $32,000. Coastal Investment Advisors Inc. acquired a new position in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $36,000. Whittier Trust Co. acquired a new position in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $42,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.

NASDAQ:ACAD traded up $1.23 during mid-day trading on Friday, reaching $46.30. 36,368 shares of the company’s stock were exchanged, compared to its average volume of 1,325,157. ACADIA Pharmaceuticals has a one year low of $14.01 and a one year high of $47.79. The firm has a market capitalization of $7.10 billion, a PE ratio of -23.86 and a beta of 2.82. The business’s fifty day simple moving average is $41.32 and its two-hundred day simple moving average is $31.42. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.89 and a current ratio of 10.96.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

See Also: How to Invest in the Dividend Aristocrat Index

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.